文献速递消化道肿瘤放疗胸部肿瘤放疗放疗物理与技术

食管癌根治性同步放化疗后心包积液研究

Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.
PubMed 文献 · Radiat Oncol · 2020-02-27

研究回顾126例接受根治性同步化疗和IMRT的食管癌患者,中位随访14.0个月,29.4%出现心包积液(中位间隔6.6个月),6.3%为≥3级。多因素分析显示平均心脏剂量、心脏V30、平均心包剂量、心包V20及心包V30/V40/V60等剂量体积参数可预测心包积液风险,可作为IMRT剂量约束参考。

要点

  • 29.4%患者出现心包积液,6.3%为≥3级症状性心包积液。
  • 平均心脏剂量>23.45 Gy、心脏V30>33.55%与任意级别心包积液相关。
  • 心包V30>65.80%、V40>55.35%、V60>24.70%与≥3级心包积液相关。

核心结论

  • 剂量体积参数可预测食管癌根治性同步化疗和IMRT后心包积液风险,可作为IMRT剂量约束。

研究设计与样本

  • 回顾性研究,纳入2008至2018年126例连续接受根治性同步化疗和IMRT的食管癌患者。
  • 心包积液经胸部CT判定,并按CTCAE 4.0分级。
  • 采用Kaplan-Meier法估计累积发生率,log-rank检验组间比较,多因素Cox比例风险回归分析危险因素。

主要发现

  • 8例(6.3%)出现心包积液相关症状,视为≥3级心包积液。
  • 任意级别心包积液累积发生率在平均心脏剂量>23.45 Gy(p=0.00018)、心脏V30>33.55%(p=0.00015)、平均心包剂量>20.33 Gy(p=0.00027)、心包V20>42.55%(p=0.00018)者中更高。
  • ≥3级心包积液累积发生率在心包V30>65.80%(p=0.00028)、V40>55.35%(p<0.0001)、V60>24.70%(p=0.0021)者中更高。
  • 多因素分析显示上述剂量体积参数可预测心包积液风险。

关键数值与推荐

  • 任意级别心包积液相关参数:平均心脏剂量>23.45 Gy、心脏V30>33.55%、平均心包剂量>20.33 Gy、心包V20>42.55%。
  • ≥3级心包积液相关参数:心包V30>65.80%、V40>55.35%、V60>24.70%。
  • 心包积液按CTCAE 4.0分级,≥3级为出现相关症状者。

临床怎么用

  • 制定食管癌IMRT计划时可参考上述心脏及心包剂量体积参数作为约束,以降低心包积液风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The literature regarding pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal cancer was lacking. This study aimed to investigate the risk factors of pericardial effusion in esophageal cancer patients undergoing definitive concurrent chemotherapy and IMRT. METHODS: A total of 126 consecutive esophageal cancer patients treated with definitive concurrent chemotherapy and IMRT between 2008 and 2018 were reviewed. The pericardial effusion was determined on computed tomography scan of the chest and graded by the Common Terminology Criteria for Adverse Events, version 4.0. The cumulative incidence of pericardial effusion was estimated by the Kaplan-Meier method and compared between groups by the log-rank test. The risk factors of pericardial effusion were determined with multivariate Cox proportional hazards regression analysis. RESULTS: The median follow-up time was 14.0 months. Thirty-seven (29.4%) patients had pericardial effusion after a median interval of 6.6 months since the end of IMRT. The cumulative incidence of pericardial effusion of any grade was higher in patients with mean heart dose > 23.45 Gy (p = 0.00018), heart V30 > 33.55% (p = 0.00015), mean pericardium dose > 20.33 Gy (p = 0.00027), and pericardium V20 > 42.55% (p = 0.00018). Furthermore, eight (6.3%) patients had symptoms related to pericardial effusion and were considered as cases with pericardial effusion ≥ grade 3. The cumulative incidence of pericardial effusion ≥ grade 3 was higher in patients with pericardium V30 > 65.80% (p = 0.00028), V40 > 55.35% (p < 0.0001), and V60 > 24.70% (p = 0.0021). Multivariate analyses showed the above dose-volume parameters predicted the risk of pericardial effusion in esophageal cancer. CONCLUSIONS: Dose-volume parameters predicting the risk of pericardial effusion were identified in esophageal cancer treated with definitive concurrent chemotherapy and IMRT. They could be applied as constraints of IMRT for esophageal cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pao TH, Chang WL, Chiang NJ, et al. Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer. Radiat Oncol. 2020. PMID: 32103779. doi:10.1186/s13014-020-01498-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。